Which has stronger earnings & valuation, GNCAQ or VRPX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genocea Biosciences N/A N/A N/A N/A N/A Virpax Pharmaceuticals N/A N/A -$15.19M -$123.25 N/A

Is GNCAQ or VRPX more profitable?

Genocea Biosciences' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Genocea Biosciences N/A N/A N/A Virpax Pharmaceuticals N/A -1,554.34% -338.29%

Which has higher valuation & earnings, NAVB or GNCAQ?

Genocea Biosciences has lower revenue, but higher earnings than Navidea Biopharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Navidea Biopharmaceuticals $8.13K 0.00 -$15.18M -$0.21 N/A Genocea Biosciences N/A N/A N/A N/A N/A

Is NAVB or GNCAQ more profitable?

Company Net Margins Return on Equity Return on Assets Navidea Biopharmaceuticals N/A N/A N/A Genocea Biosciences N/A N/A N/A

Which has stronger earnings and valuation, GNCAQ or GNCA?

Genocea Biosciences has higher earnings, but lower revenue than Genocea Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genocea Biosciences N/A N/A N/A N/A N/A Genocea Biosciences $1.91M 0.00 -$33.20M -$0.61 N/A

Is GNCAQ or GNCA more profitable?

Genocea Biosciences' return on equity of 0.00% beat Genocea Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Genocea Biosciences N/A N/A N/A Genocea Biosciences N/A -182.88% -62.76%

Which has higher valuation and earnings, PXMD or GNCAQ?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PaxMedica N/A N/A -$18.29M -$6.09 N/A Genocea Biosciences N/A N/A N/A N/A N/A

Is PXMD or GNCAQ more profitable?

Genocea Biosciences' return on equity of 0.00% beat PaxMedica's return on equity. Company Net Margins Return on Equity Return on Assets PaxMedica N/A -3,167.89% -560.35% Genocea Biosciences N/A N/A N/A

Which has stronger earnings & valuation, GNCAQ or ARDS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genocea Biosciences N/A N/A N/A N/A N/A Aridis Pharmaceuticals N/A N/A -$30.37M $0.09 N/A

Is GNCAQ or ARDS more profitable?

Company Net Margins Return on Equity Return on Assets Genocea Biosciences N/A N/A N/A Aridis Pharmaceuticals N/A N/A N/A

Genocea Biosciences (GNCAQ) Competitors

Compare

GNCAQ vs. VRPX, NAVB, GNCA, PXMD, and ARDS

Should you buy Genocea Biosciences stock or one of its competitors? MarketBeat compares Genocea Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Genocea Biosciences include Virpax Pharmaceuticals (VRPX), Navidea Biopharmaceuticals (NAVB), Genocea Biosciences (GNCA), PaxMedica (PXMD), and Aridis Pharmaceuticals (ARDS). These companies are all part of the "pharmaceutical products" industry.

How does Genocea Biosciences compare to Virpax Pharmaceuticals?

Genocea Biosciences (NASDAQ:GNCAQ) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

Genocea Biosciences has a beta of 2.44, indicating that its stock price is 144% more volatile than the broader market. Comparatively, Virpax Pharmaceuticals has a beta of -16.52, indicating that its stock price is 1,752% less volatile than the broader market.

32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by insiders. Comparatively, 3.7% of Virpax Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Virpax Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Genocea Biosciences	Neutral
Virpax Pharmaceuticals	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genocea Biosciences	N/A	N/A	N/A	N/A	N/A
Virpax Pharmaceuticals	N/A	N/A	-$15.19M	-$123.25	N/A

Genocea Biosciences' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genocea Biosciences	N/A	N/A	N/A
Virpax Pharmaceuticals	N/A	-1,554.34%	-338.29%

Summary

Genocea Biosciences and Virpax Pharmaceuticals tied by winning 3 of the 6 factors compared between the two stocks.

How does Genocea Biosciences compare to Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals (NYSE:NAVB) and Genocea Biosciences (NASDAQ:GNCAQ) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are owned by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Navidea Biopharmaceuticals has a beta of 1.76, indicating that its share price is 76% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 2.44, indicating that its share price is 144% more volatile than the broader market.

Genocea Biosciences has lower revenue, but higher earnings than Navidea Biopharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Navidea Biopharmaceuticals	$8.13K	0.00	-$15.18M	-$0.21	N/A
Genocea Biosciences	N/A	N/A	N/A	N/A	N/A

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company	Overall Sentiment
Navidea Biopharmaceuticals	Neutral
Genocea Biosciences	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Navidea Biopharmaceuticals	N/A	N/A	N/A
Genocea Biosciences	N/A	N/A	N/A

Summary

Navidea Biopharmaceuticals beats Genocea Biosciences on 3 of the 5 factors compared between the two stocks.

How does Genocea Biosciences compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCAQ) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

0.6% of Genocea Biosciences shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company	Overall Sentiment
Genocea Biosciences	Neutral
Genocea Biosciences	Neutral

Genocea Biosciences' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genocea Biosciences	N/A	N/A	N/A
Genocea Biosciences	N/A	-182.88%	-62.76%

Genocea Biosciences has a beta of 2.44, suggesting that its share price is 144% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 1.61, suggesting that its share price is 61% more volatile than the broader market.

Genocea Biosciences has higher earnings, but lower revenue than Genocea Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genocea Biosciences	N/A	N/A	N/A	N/A	N/A
Genocea Biosciences	$1.91M	0.00	-$33.20M	-$0.61	N/A

Summary

Genocea Biosciences beats Genocea Biosciences on 4 of the 6 factors compared between the two stocks.

How does Genocea Biosciences compare to PaxMedica?

PaxMedica (NASDAQ:PXMD) and Genocea Biosciences (NASDAQ:GNCAQ) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PaxMedica	N/A	N/A	-$18.29M	-$6.09	N/A
Genocea Biosciences	N/A	N/A	N/A	N/A	N/A

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company	Overall Sentiment
PaxMedica	Neutral
Genocea Biosciences	Neutral

Genocea Biosciences' return on equity of 0.00% beat PaxMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PaxMedica	N/A	-3,167.89%	-560.35%
Genocea Biosciences	N/A	N/A	N/A

4.9% of PaxMedica shares are held by institutional investors. 1.0% of PaxMedica shares are held by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

PaxMedica has a beta of -0.99, indicating that its share price is 199% less volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 2.44, indicating that its share price is 144% more volatile than the broader market.

Summary

Genocea Biosciences beats PaxMedica on 4 of the 6 factors compared between the two stocks.

How does Genocea Biosciences compare to Aridis Pharmaceuticals?

Genocea Biosciences (NASDAQ:GNCAQ) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.

9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Genocea Biosciences	Neutral
Aridis Pharmaceuticals	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genocea Biosciences	N/A	N/A	N/A	N/A	N/A
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	$0.09	N/A

Genocea Biosciences has a beta of 2.44, meaning that its stock price is 144% more volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 44.97, meaning that its stock price is 4,397% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Genocea Biosciences	N/A	N/A	N/A
Aridis Pharmaceuticals	N/A	N/A	N/A

Summary

Aridis Pharmaceuticals beats Genocea Biosciences on 4 of the 4 factors compared between the two stocks.

Get Genocea Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNCAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

GNCAQ vs. The Competition

Export

Metric	Genocea Biosciences	Biological Products Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5K	$353.15M	$7.16B	$12.48B
Dividend Yield	N/A	N/A	2.66%	6.52%
P/E Ratio	0.00	N/A	28.02	24.70
Price / Sales	N/A	228.84	540.37	99.49
Price / Cash	N/A	22.44	49.26	57.09
Price / Book	N/A	4.86	10.96	6.46
Net Income	N/A	-$141.03M	$3.57B	$337.01M

Genocea Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
GNCAQ Genocea Biosciences	N/A	N/A	N/A	N/A	$5K	N/A	N/A	70
VRPX Virpax Pharmaceuticals	N/A	$0.01 flat	N/A	-97.1%	$14K	N/A	N/A	7
NAVB Navidea Biopharmaceuticals	N/A	N/A	N/A	N/A	$10K	$8.13K	N/A	10
GNCA Genocea Biosciences	N/A	N/A	N/A	N/A	$6K	$1.91M	N/A	70
PXMD PaxMedica	N/A	$0.00 flat	N/A	N/A	$6K	N/A	N/A	2

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GNCAQ) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genocea Biosciences (GNCAQ) Competitors

GNCAQ vs. VRPX, NAVB, GNCA, PXMD, and ARDS

How does Genocea Biosciences compare to Virpax Pharmaceuticals?

Summary

How does Genocea Biosciences compare to Navidea Biopharmaceuticals?

Summary

How does Genocea Biosciences compare to Genocea Biosciences?

Summary

How does Genocea Biosciences compare to PaxMedica?

Summary

How does Genocea Biosciences compare to Aridis Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

GNCAQ vs. The Competition

Genocea Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Genocea Biosciences (GNCAQ) Competitors

GNCAQ vs. VRPX, NAVB, GNCA, PXMD, and ARDS

How does Genocea Biosciences compare to Virpax Pharmaceuticals?

Which has more volatility and risk, GNCAQ or VRPX?

Do insiders and institutionals hold more shares of GNCAQ or VRPX?

Does the media prefer GNCAQ or VRPX?

Which has stronger earnings & valuation, GNCAQ or VRPX?

Is GNCAQ or VRPX more profitable?

Summary

How does Genocea Biosciences compare to Navidea Biopharmaceuticals?

Do insiders and institutionals believe in NAVB or GNCAQ?

Which has more volatility and risk, NAVB or GNCAQ?

Which has higher valuation & earnings, NAVB or GNCAQ?

Does the media refer more to NAVB or GNCAQ?

Is NAVB or GNCAQ more profitable?

Summary

How does Genocea Biosciences compare to Genocea Biosciences?

Do insiders and institutionals have more ownership in GNCAQ or GNCA?

Does the media favor GNCAQ or GNCA?

Is GNCAQ or GNCA more profitable?

Which has more volatility & risk, GNCAQ or GNCA?

Which has stronger earnings and valuation, GNCAQ or GNCA?

Summary

How does Genocea Biosciences compare to PaxMedica?

Which has higher valuation and earnings, PXMD or GNCAQ?

Does the media prefer PXMD or GNCAQ?

Is PXMD or GNCAQ more profitable?

Do institutionals & insiders believe in PXMD or GNCAQ?

Which has more volatility & risk, PXMD or GNCAQ?

Summary

How does Genocea Biosciences compare to Aridis Pharmaceuticals?

Do insiders and institutionals have more ownership in GNCAQ or ARDS?

Does the media refer more to GNCAQ or ARDS?

Which has stronger earnings & valuation, GNCAQ or ARDS?

Which has more volatility and risk, GNCAQ or ARDS?

Is GNCAQ or ARDS more profitable?

Summary

New MarketBeat Followers Over Time

GNCAQ vs. The Competition

Genocea Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools